Net Income Common - Viridian Therapeutics Inc (NASDAQ:VRDN) - Alpha Spread

Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 22.5 USD 6.84% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Viridian Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Viridian Therapeutics Inc
Net Income (Common) Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Viridian Therapeutics Inc
NASDAQ:VRDN
Net Income (Common)
-$228.1m
CAGR 3-Years
-20%
CAGR 5-Years
-42%
CAGR 10-Years
-46%
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.3B
CAGR 3-Years
-7%
CAGR 5-Years
5%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$1.1B
CAGR 3-Years
-41%
CAGR 5-Years
-29%
CAGR 10-Years
-18%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$3.1B
CAGR 3-Years
-18%
CAGR 5-Years
-17%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$489.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
0%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.3B
CAGR 3-Years
-11%
CAGR 5-Years
16%
CAGR 10-Years
27%

See Also

What is Viridian Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-228.1m USD

Based on the financial report for Jun 30, 2024, Viridian Therapeutics Inc's Net Income (Common) amounts to -228.1m USD.

What is Viridian Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-46%

Over the last year, the Net Income (Common) growth was -15%. The average annual Net Income (Common) growth rates for Viridian Therapeutics Inc have been -20% over the past three years , -42% over the past five years , and -46% over the past ten years .

Back to Top